KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Astrazeneca (AZN) Revenue (2016 - 2025)

Historic Revenue for Astrazeneca (AZN) over the last 16 years, with Q4 2025 value amounting to $15.5 billion.

  • Astrazeneca's Revenue rose 410.99% to $15.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $58.7 billion, marking a year-over-year increase of 862.91%. This contributed to the annual value of $58.7 billion for FY2025, which is 862.91% up from last year.
  • Astrazeneca's Revenue amounted to $15.5 billion in Q4 2025, which was up 410.99% from $15.2 billion recorded in Q3 2025.
  • In the past 5 years, Astrazeneca's Revenue registered a high of $15.5 billion during Q4 2025, and its lowest value of $158.0 million during Q4 2022.
  • Over the past 5 years, Astrazeneca's median Revenue value was $11.8 billion (recorded in 2021), while the average stood at $10.4 billion.
  • As far as peak fluctuations go, Astrazeneca's Revenue plummeted by 9868.45% in 2022, and later surged by 751012.66% in 2023.
  • Quarter analysis of 5 years shows Astrazeneca's Revenue stood at $12.0 billion in 2021, then tumbled by 98.68% to $158.0 million in 2022, then soared by 7510.13% to $12.0 billion in 2023, then increased by 23.84% to $14.9 billion in 2024, then increased by 4.11% to $15.5 billion in 2025.
  • Its last three reported values are $15.5 billion in Q4 2025, $15.2 billion for Q3 2025, and $14.5 billion during Q2 2025.